I believe this was the reason NP has previously mentioned the difficulty of doing things differently than big pharmaceutical are accustomed to. Licensing out only certain indications vs all indications for a specific drug? Does anyone know of a similar license deal where only certain rights were given up while others were maintained? Seems most of the deals I have seen are for all indications for the drug?

The name change that ohm mentions seems like this has happened previously, just curious how common this is and if anything with the huge potential markets we are talking with leronlimab?